Allarity Therapeutics Inc... (ALLR)
0.81
-0.03 (-3.74%)
At close: Apr 16, 2025, 9:57 AM
-3.74% (1D)
| Bid | 0.58 |
| Market Cap | 13.84M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -25.08M |
| EPS (ttm) | -15.65 |
| PE Ratio (ttm) | -0.05 |
| Forward PE | -0.02 |
| Analyst | n/a |
| Ask | 1.05 |
| Volume | 133,197 |
| Avg. Volume (20D) | 2,368,706 |
| Open | 0.84 |
| Previous Close | 0.84 |
| Day's Range | 0.81 - 0.84 |
| 52-Week Range | 0.61 - 103.80 |
| Beta | -0.07 |
About ALLR
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microt...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 21, 2021
Employees 6
Stock Exchange NASDAQ
Ticker Symbol ALLR
Website https://www.allarity.com
2 weeks ago
-9.91%
Allarity Therapeutics shares are trading higher af...
Unlock content with
Pro Subscription
1 month ago
+10.19%
Allarity Therapeutics shares are trading higher after the company's board announced a $5 million share repurchase program.
